Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05782283 · ClinicalTrials.gov registry record · NA
A Study to Detect Advanced Liver Disease Via AI-enabled Electrocardiogram
A NA study, sponsored by Mayo Clinic.
- Completed
- Registry status
- NA
- Development phase
- 279
- Enrollment target
NCT05782283: Completed NA study, sponsored by Mayo Clinic.
NCT05782283 is a NA study that has completed, run by Mayo Clinic. The registered enrollment target is 279 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (80% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05782283, a NA study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 279 participants
- Enrollment target
Study Summary
The overall objectives of this study are to determine the effectiveness of ACE 2.0 model in early detection of advanced liver fibrosis, and to determine the acceptance and barriers for use of an AI-enabled algorithm for prediction of liver disease in primary care.
Primary Outcome
Number of participants with new diagnosis of advanced liver disease as assessed by a novel electrocardiogram-enabled convoluted neural network (CNN) compared to standard of care at 6 months.
Interventions
- DEVICE ACE (AI-Cirrhosis-ECG) 2.0
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 279 participants |
| Start Date | 2023-04-18 |
| Est. Completion | 2025-09-01 |
| Phase | NA |
What the finished NCT05782283 record still lists
NCT05782283 is an interventional study that assigns participants to a tested intervention. The registered 279 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (80% lower).
The record links to 0 conditions, and to 1 intervention - of which ACE (AI-Cirrhosis-ECG) 2.0 is the first listed.
NCT05782283 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05782283 about?
NCT05782283 is a clinical study titled "A Study to Detect Advanced Liver Disease Via AI-enabled Electrocardiogram". The overall objectives of this study are to determine the effectiveness of ACE 2.0 model in early detection of advanced liver fibrosis, and to determine the acceptance and barriers for use of an AI-enabled algorithm for prediction of liver disease in primary care.
What is the current status of trial NCT05782283?
This trial is currently completed. It is a NA study. The enrollment target is 279 participants. The study started on 2023-04-18. Estimated completion is 2025-09-01.
What interventions are being tested in trial NCT05782283?
The interventions under investigation include: ACE (AI-Cirrhosis-ECG) 2.0 (DEVICE).
Who is sponsoring clinical trial NCT05782283?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05782283's enrollment target sits among peer trials
279 381st of 2000 higher than 1,619 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04783857 · 279 participants · Phase 4
Modifying Progesterone and Estradiol Levels to Prevent Postpartum Cigarette Smoking Relapse and Reduce Secondhand Smoke Exposure in Infants and Children
- NCT05407324 · 279 participants · Phase 2
Dazucorilant in Patients With Amyotrophic Lateral Sclerosis
- NCT06299748 · 279 participants
A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.
- NCT06582784 · 279 participants · NA
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI